Compare Amphastar Pharmaceuticals Inc (AMPH) vs RLX Technology Inc (RLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs RLX Technology Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while RLX Technology Inc trades at $1.96 (market cap $2.38B). The key difference: RLX Technology Inc is far larger — about 2.9× Amphastar Pharmaceuticals Inc's market cap, and RLX Technology Inc pays a 5.13% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RLX | |
|---|---|---|
Market Cap | $826.08M | $2.38B |
Sector | Health | Technology |
52-Week High | $30.81 | $2.73 |
52-Week Low | $16.87 | $1.79 |
Enterprise Value | $1.22B | $1.02B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
RLX trades at $1.95, down 2.01% today, amid mixed technical signals with a neutral overall outlook. The company reported strong 2025 fundamentals with $3.62B revenue and $922M net income, though recent quarterly EPS results have missed expectations. Analyst coverage is limited to a single hold rating, while news highlights international expansion and a cash-rich, debt-free balance sheet.
The outlook is cautious due to earnings misses and a neutral technical stance, but the company's profitability, growth potential in the vaping industry, and solid financial health present a long-term opportunity. Key risks include regulatory pressures and competitive threats in the e-cigarette market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
